Pituitary gland: Mortality in acromegaly reduced with multimodal therapy

Nature Reviews Endocrinology

Volumn 10, Issue 12, 2014, Pages 708-710

  Biermasz, Nienke R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PEGVISOMANT; SOMATOSTATIN DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; SOMATOSTATIN;

ACROMEGALY; COMORBIDITY; DIABETES MELLITUS; DISEASE CONTROL; HEART DISEASE; HUMAN; HYPERTENSION; HYPOPITUITARISM; MORTALITY; MULTIMODAL CHEMOTHERAPY; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL RATE; TRANSSPHENOIDAL SURGERY; ADENOMA; ANALOGS AND DERIVATIVES; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; NEUROSURGERY; RADIOTHERAPY;

ADENOMA; ANTINEOPLASTIC AGENTS, HORMONAL; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; NEUROSURGICAL PROCEDURES; RADIOTHERAPY; SOMATOSTATIN;

EID: 84927177047     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.193     Document Type: Short Survey

References (10)

1. Mercado, M. et al. Successful mortality reduction and control of co-morbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J. Clin. Endocrinol. Metab. http://press.endocrine.org/doi/abs/10.1210/jc.2014-2670.
2. Dekkers, O. M., Biermasz, N. R., Pereira, A. M., Romijn, J. A. & Vandenbroucke, J. P. Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 93, 61-67 (2008).
3. Holdaway I. M., Bolland M. J. & Gamble G. D. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159, 89-95 (2008).
4. Sherlock, M. et al. Mortality in patients with pituitary disease. Endocr. Rev. 31, 301-342 (2010).
5. Melmed S. et al. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94, 1509-1517 (2009).
6. Bogazzi F. et al. Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. Eur. J. Endocrinol. 169, 367-376 (2013).
7. Biermasz N. R. et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J. Clin. Endocrinol. Metab. 89, 2789-2796 (2004).
8. Swearingen B. et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. 83, 3419-3426 (1998).
9. Sherlock, M. et al. A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. J. Clin. Endocrinol. Metab. 99, 478-485 (2014).
10. Burgers, A. M. et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. J. Clin. Endocrinol. Metab. 96, 2912-2920 (2011).